TP53 and myelodysplastic syndrome: The prevalence of TP53 mutation in de Novo AML, secondary AML, MDS-EB and therapy related AML/MDS (T-AML/MDS) are 5–10%, 4%, 15–60% and 30–50%, respectively [1–8].